Merus (NASDAQ:MRUS) Receives $85.31 Average Price Target from Analysts

Merus (NASDAQ:MRUS) has been given an average rating of “Buy” by the sixteen analysts that are covering the company, Marketbeat.com reports. Fourteen investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $85.15.

A number of brokerages have issued reports on MRUS. HC Wainwright reissued a “buy” rating and set a $85.00 target price on shares of Merus in a report on Monday, March 3rd. William Blair reiterated an “outperform” rating on shares of Merus in a research note on Monday, April 28th. Bank of America cut their target price on Merus from $73.00 to $70.00 and set a “buy” rating for the company in a research note on Monday, March 10th. Wells Fargo & Company decreased their price target on Merus from $91.00 to $89.00 and set an “overweight” rating on the stock in a research report on Thursday. Finally, Guggenheim restated a “buy” rating and issued a $109.00 price objective on shares of Merus in a research report on Friday, March 28th.

Hedge Funds Weigh In On Merus

A number of large investors have recently modified their holdings of MRUS. GAMMA Investing LLC grew its position in Merus by 2,153.6% during the first quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 603 shares during the last quarter. State of Wyoming bought a new position in shares of Merus during the 4th quarter valued at $48,000. Wells Fargo & Company MN grew its holdings in shares of Merus by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 300 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Merus in the 4th quarter worth $60,000. Finally, Avior Wealth Management LLC bought a new stake in Merus in the fourth quarter worth $76,000. 96.14% of the stock is owned by hedge funds and other institutional investors.

Merus Stock Performance

Shares of MRUS stock opened at $42.77 on Friday. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of -10.83 and a beta of 0.94. Merus has a 52 week low of $33.19 and a 52 week high of $61.61. The firm’s 50-day simple moving average is $43.63 and its two-hundred day simple moving average is $44.30.

Merus (NASDAQ:MRUS) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.23). The business had revenue of $26.49 million for the quarter, compared to analysts’ expectations of $7.82 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. Analysts forecast that Merus will post -3.85 earnings per share for the current year.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.